Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 7/20 | 0.41 |
| ▸ | ATP4B | P51164 | 7/20 | 0.41 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.41 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.41 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.41 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.41 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.41 |
| ▸ | ATP1B3 | P54709 | 3/20 | 0.41 |
| ▸ | FXYD2 | P54710 | 3/20 | 0.41 |
| ▸ | ATP1A4 | Q13733 | 3/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9527234 | 0.92 | ATP4A (0.42) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL28815215 | 0.91 | NOS2 (0.40) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL10372859 | 0.90 | ATP4A (0.38) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL10370234 | 0.90 | ATP4A (0.38) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL6482588 | 0.89 | ATP4A (0.44) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL6883715 | 0.87 | ATP4A (0.43) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL6882608 | 0.87 | ATP4A (0.55) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL9527842 | 0.85 | NOS2 (0.40) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL6873292 | 0.85 | NOS2 (0.40) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL2873599 | 0.85 | ATP4A (0.53) | ATP4AATP4BATP1A1ATP1B1ATP1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | ATOPIX THERAPEUTICS LTD (GB) | 2014-11-06 | — | — | US | disclosed |
| US-7683177-B2 | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2010-03-23 | — | — | US | disclosed |
| US-7683177-B2 | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2010-03-23 | — | — | US | disclosed |
| WO-2008001392-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF PANTOPRAZOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004319-A1 | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole | BRAUDE VIVIANA | 2008-01-03 | — | — | US | disclosed |
| US-20080004319-A1 | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole | BRAUDE VIVIANA | 2008-01-03 | — | — | US | disclosed |
| EP-1615913-A2 | PROCESS FOR PREPARING 2-(PYRIDINYL)METHYL SULFINYL-SUBSTITUTED BENZIMIDAZOLES AND NOVEL CHLORINATED DERIVATIVES OF PANTOPRAZOLE | Teva Pharmaceutical Industries Limited (IL) | 2006-01-18 | — | — | EP | disclosed |
| US-20050075370-A1 | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole | TEVA PHARMACEUTICALS USA, INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2004111029-A2 | PROCESS FOR PREPARING 2-[(PYRIDINYL)METHYL]SULFINYL-SUBSTITUTED BENZIMIDAZOLES AND NOVEL CHLORINATED DERIVATIVES OF PANTOPRAZOLE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-12-23 | — | — | WO | disclosed |
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | SOHNSTEARNS & STERN | 2004-12-23 | — | — | US | disclosed |
| EP-0166287-B1 | DIALKOXYRIDINES, PROCESS FOR THEIR PREPARATION, THEIR APPLICATION AND MEDICAMENTS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1989-08-23 | — | — | EP | disclosed |
| US-4758579-A | e.g. pantoprazole or pantoprazole sodium | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-07-19 | — | — | US | disclosed |
| EP-0166287-A1 | Dialkoxyridines, process for their preparation, their application and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1986-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004319-A1 | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole | RAB29, SQOR, RAB35 | ATP4A 558/4885ATP4B 697/4885ATP1A1 414/4885 |
| US-20050075370-A1 | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole | RAB29, SQOR, RAB35 | ATP4A 558/4885ATP4B 697/4885ATP1A1 414/4885 |
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | HRH2, HRH1, HRH4 | ATP4A 298/4885ATP4B 428/4885ATP1A1 318/4885 |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | HRH2, HRH1, HRH4 | ATP4A 1229/4885ATP4B 990/4885ATP1A1 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.